ICT startups receive CTI startup Label

Embotech, Nispera, Optimo Medical and SimplicityBio have been awarded the CTI Startup Label. Although the companies are active in very different industries they have one thing in common: They focus on digitisation. 

Digitisation is a promising field for Swiss ICT start-ups with their scientific background. To be successful it usually needs cutting edge software and a deep understanding of the application field. Good examples are the four new CTI Startup label companies. They are active in different industries but all are offering solutions designed to enhance performance, increase efficiency and facilitate decision making.

The startups completed the CTI coaching and have been awarded the CTI Startup Label by the Certification Board – comprising of seasoned entrepreneurs and experts – of the Swiss Commission for Technology and Innovation. The Label acts as a symbol of maturity and market readiness. The four start-ups are: 

Embotech AG, Zürich
Zurich based startup embotech developed a numerical optimization software which powers complex real-time decision making engines in a variety of applications. The software promotes new ways of building and designing optimal decision making systems such as autonomous machines ranging from a dishwasher to complex air traffic control systems. This results in reduced development cost, increased productivity and reliability.

In the field of computational finance, embotech’s backend software for mathematical optimization, which is 100x faster than state-of-the-art, enables real-time, interactive portfolio optimization on mobile devices. Another example from a totally different application field is a project with the European Space Agency (ESA). Following the launch of their software development project together with the Future Launchers Preparatory Program (FLPP) of ESA in 2016, the startup was selected as a member of the Swiss ESA Business Incubator in May. 

Zurich-based startup Nìspera established by former Axpo employees offers solutions that enable renewable power asset stakeholders to enhance the performance of their investments. The service includes several offerings such as portfolio monitoring - owners are provided with expert advice and on-line monitoring tools to enhance the performance of their assets - , and Asset Management managerial assistance in order to maximise the value generation from the assets. In addition Nispera offers best-in-class forecast solutions in response to the power market’s dynamic requirements. Nìspera also provides customized solutions for the power industry in the areas of market data analysis, origination support and more.

Optimo Medical AG, Biel/Bienne
Established in 2015, the startup is dedicated to enhancing results in eye surgery. With its technology «Optimeyes», the startup makes surgical procedures on the human cornea safer and more precise. The software predicts the influence of physical interventions in the cornea in a patient-specific way, thus allowing it to simulate and evaluate treatment results in the intervention planning phase. Additionally, it enables surgeons to know exactly where to place the incisions and can ascertain that the patient’s eyesight will be restored. The first version of Optimeyes will be launched as a class IIb medical device in Q3/2017. 

SimplicityBio SA, Monthey
Established as a spin-off from the University of Applied Sciences Western Switzerland and incubated at the BioArk in Monthey, SimplicityBio supports biotech and medtech companies create robust signatures models by using a panel of biomarkers based on genomics, proteomics or metabolomics data. These models can be used, for instance, to bring molecular diagnostic tests to market, or for patient stratification in order to develop more effective medicaments. Partners of SimplicityBio include TATAA Biocenter, Europe's leading provider of genomic services and the world's foremost organizer of hands-on training in molecular diagnostics, and TAmiRNA, a biotech company specialized in the identification and validation of biomarkers for age-related diseases.